Sexual Wellness
PT-141 (Bremelanotide)
An FDA-approved melanocortin peptide for low sexual desire that acts on the brain, not blood flow.
Also called: bremelanotide, Vyleesi, PT141
Used for
Sexual Wellness
Our pricing
$100 to $1,000+ depending on peptide and quantity
Studied for
Low sexual desire in premenopausal women (approved use) · Erectile dysfunction and low libido in men (off-label)
PT-141 (bremelanotide) is a synthetic peptide that activates melanocortin-4 receptors in the brain, influencing desire pathways rather than blood flow. It is FDA-approved under the brand name Vyleesi as an as-needed injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women; use in men and in postmenopausal women is off-label. Whether it is appropriate for you, in brand or compounded form, is a decision your nurse practitioner makes after a health history and blood-pressure check.
What is PT-141 (Bremelanotide)?
Bremelanotide descends from a line of tanning peptides. Researchers modifying alpha-melanocyte-stimulating hormone in the 1990s noticed that one analog, Melanotan II, produced unexpected sexual effects in early testing, and PT-141 was developed from it specifically for that purpose. Early versions were a nasal spray, abandoned because of blood-pressure increases; the approved form is a subcutaneous autoinjector, approved by the FDA in June 2019.
Its mechanism sets it apart from erectile-dysfunction drugs. Sildenafil and similar medications act on blood vessels; PT-141 acts centrally, on melanocortin receptors in the hypothalamus that are involved in sexual motivation. That is why it is studied for desire rather than performance, and why it is discussed for people whose main complaint is low interest rather than low response.
The approval evidence comes from two Phase 3 trials of roughly 1,200 premenopausal women with hypoactive sexual desire disorder. Compared with placebo, bremelanotide produced statistically significant improvements in desire and in distress about low desire, and many patients describe that improvement as meaningful in daily life. Evidence in men is older and smaller, mostly from the nasal-spray era, and no product has been approved for men.
What PT-141 (Bremelanotide) is studied for
The goals researchers and clinicians have focused on, and why patients ask about it.
Low sexual desire in premenopausal women (approved use)
The FDA-approved indication is acquired, generalized hypoactive sexual desire disorder: low desire that developed after a period of normal desire, occurs regardless of partner or situation, and causes distress. Two Phase 3 trials showed meaningful improvements over placebo, and patients frequently describe renewed interest and less distress around low desire. It is not approved for desire problems caused by another condition, a relationship issue or a medication.
Erectile dysfunction and low libido in men (off-label)
Small studies from the early 2000s, mostly with nasal bremelanotide, reported improved erections in men, including some who did not respond to sildenafil — a pattern many men using it off-label say matches their experience. Development for men was never completed, so use is off-label and research is still catching up to that real-world use.
Postmenopausal women (off-label)
Postmenopausal women were excluded from the approval trials, and some patients in this group who use it off-label alongside hormone therapy report improved desire; research specific to this group is still catching up to the approved indication.
Desire that persists after hormone optimization
Clinically, PT-141 is discussed for people whose hormone levels have been addressed but whose desire remains low, and patients in this situation often say it helps close the remaining gap. There is no trial specifically testing that sequence; it is a reasoned clinical use guided by that real-world pattern.
The human side
What patients commonly report with PT-141 (Bremelanotide)
Clinical trials move slowly; patient experience moves faster. Here is what people using PT-141 (Bremelanotide) under clinical supervision most often describe. Results vary from person to person.
Renewed interest in intimacy and less distress about low desire
A noticeable lift within a few hours of use, timed around planned intimacy
Better response when paired with hormone optimization
Increased confidence and connection in relationships
How PT-141 (Bremelanotide) is typically used
The approved product is an as-needed subcutaneous injection into the abdomen or thigh, taken a set time before anticipated sexual activity rather than daily. The label limits how often it can be used within a day and a month; those limits and the timing window are reviewed with you and are not published here.
Before any use, a health history and a blood-pressure check are essential, because bremelanotide transiently raises blood pressure. People with uncontrolled hypertension or known cardiovascular disease should not use it. A trial of several uses with a defined review point is a reasonable way to judge whether it helps.
Compounded PT-141 is marketed as injections, nasal sprays and dissolving tablets at lower cost than the brand. These are prepared by pharmacies under separate rules and have not been FDA-reviewed for quality or effectiveness; that trade-off is worth a candid conversation with your nurse practitioner.
Who tends to do well with it
Premenopausal women with distressing low desire that is not explained by a medical condition, relationship factors or a medication
Men with libido-driven sexual difficulties who understand use is off-label and have discussed proven options first
Patients whose hormones have been optimized in a bioidentical hormone program but whose desire remains a concern
People who want an as-needed option and are comfortable with self-injection and the nausea trade-off
When we take extra care
Anyone with uncontrolled high blood pressure or known cardiovascular disease (contraindicated)
People taking oral naltrexone, because bremelanotide can lower its absorption and reduce its effect
Pregnant patients or anyone planning pregnancy (the label advises stopping if pregnancy occurs)
People with darker skin, who are more likely to develop patches of skin darkening with repeated use
Anyone with severe kidney or liver impairment
Anyone whose low desire has not been evaluated for depression, medication side effects or relationship causes first
What to know before you start
Nausea is very common, affecting roughly 40 percent of trial participants, and is the main reason people stop; it is usually worst with the first uses.
Flushing, injection-site reactions and headache are also common.
Blood pressure rises temporarily after each dose and heart rate can slow; this is why it is contraindicated in uncontrolled hypertension and cardiovascular disease.
Repeated use can cause focal hyperpigmentation (darkening of the face, gums or breasts), more likely in people with darker skin, and it may not fully fade.
It slows stomach emptying, which can change how quickly oral medications are absorbed.
Compounded versions vary in purity and potency and have not been reviewed by the FDA.
Where PT-141 (Bremelanotide) stands with the FDA
Bremelanotide is FDA-approved as Vyleesi, an as-needed subcutaneous autoinjector for acquired, generalized hypoactive sexual desire disorder in premenopausal women; approval came in June 2019. Use in men and in postmenopausal women is off-label, which is legal but means the evidence is thinner and the FDA has not evaluated those uses. Compounded PT-141 products are prepared under pharmacy rules that differ from drug approval and are not FDA-reviewed. whether brand or compounded bremelanotide is appropriate for you is decided at your consultation.
Source: FDA compounding guidanceWhat PT-141 (Bremelanotide) typically costs
At Hormones + Weight Loss, peptide pricing runs from about $100 to $1,000 or more depending on the peptide and the quantity you order, and many patients start with a single peptide on a short cycle. Your exact cost is quoted after your consultation.
Brand Vyleesi vs. compounded injection, nasal spray or dissolving tablet
How many doses per month you use, since it is taken as needed
Insurance coverage for the brand product and whether consultation is bundled
Often combined with
Peptides are an add-on, not a plan. At Hormones + Weight Loss they are considered inside a broader, lab-guided program.
PT-141 (Bremelanotide) FAQs
PT-141 (bremelanotide) activates melanocortin receptors in the brain that influence sexual desire. Unlike erectile-dysfunction pills, it does not work on blood flow. In trials of premenopausal women with low desire it produced modest improvements in desire and distress compared with placebo, taken as an as-needed injection.
Yes, as Vyleesi, approved in June 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Use in men or after menopause is off-label. Compounded PT-141 sold at lower cost is prepared under pharmacy rules and has not been FDA-reviewed for quality or effectiveness.
Many men using it off-label report improved erections and desire, including some who did not respond to sildenafil, though development for men was never completed as an approved product. Any use in men is off-label and should follow evaluation of hormones, blood pressure and proven options.
Nausea is the big one, affecting about 40 percent of trial participants, along with flushing, injection-site reactions and headache. Blood pressure rises briefly after each dose. Repeated use can darken patches of skin, especially in people with darker skin, and that darkening may not fully fade.
Anyone with uncontrolled high blood pressure or known cardiovascular disease, because each dose raises blood pressure. Caution also applies to people on oral naltrexone, those who are pregnant or planning pregnancy, people with severe kidney or liver problems, and anyone whose low desire has not been evaluated for other causes.
Peptide therapy at Hormones + Weight Loss ranges from about $100 to $1,000 or more, depending on the peptide and the quantity ordered. Where PT-141 (Bremelanotide) lands inside that range depends on the form, the cycle length and whether it is combined with other care. Your exact cost is quoted after your consultation and labs.
Hormones + Weight Loss discusses sexual-wellness options, including PT-141, at our Meridian, Twin Falls and Lewiston clinics, with Boise-area patients seen in Meridian. A consultation with a nurse practitioner, including a blood-pressure check, determines whether bremelanotide is appropriate for you and in which form.
Related peptides
Recovery & Healing
BPC-157
A gut-derived peptide studied for tendon, ligament, muscle and gut repair.
Growth-Hormone Support
Sermorelin
A GHRH analog studied for prompting your own pituitary to release growth hormone.
Skin, Hair & Anti-Aging
GHK-Cu
A naturally occurring copper peptide studied for collagen, wound healing and skin appearance.
Peptide therapy near you in Idaho
Consultations at all three clinics. Boise-area patients are seen at our Meridian clinic, minutes off Eagle Road and I-84.
Meridian
2572 N Stokesberry Pl #300
Meridian, ID 83646
Mon–Fri 8am–6pm
Twin Falls
496 Shoup Ave West Ste E
Twin Falls, ID 83301
Mon–Thu 8am–6pm
Lewiston
1630 23rd Ave Ste 1201A
Lewiston, ID 83501
Mon–Wed 8am–6pm
Educational content only. It does not replace an evaluation by a licensed clinician. Whether a peptide fits you is decided at your consultation.
Wondering whether PT-141 (Bremelanotide) fits your goals?
Start with a consultation and labs. A nurse practitioner will walk through the evidence, the current rules, and whether any peptide belongs in your plan.